Tasigna Atherosclerosis

Information on Tasigna Atherosclerosis, Peripheral Arterial Disease, and Amputation

Tasigna Atherosclerosis Warning

Researchers have known about the link between Tasigna and peripheral arterial disease since 2011. The drug's maker, Novartis, became aware of the danger at the same time. Yet the company did not adequately warn patients or doctors, and many Americans have suffered immeasurably and lost their lives as a result. Read this page for full information about Tasigna atherosclerosis, peripheral arterial disease, and information about filing a Tasigna lawsuit.

Understanding Tasigna Atherosclerosis

Tasigna (nilotinib) is a pharmaceutical drug approved to treat Philadelphia chromosome-positive myeloid leukemia in its chronic form. Given in oral capsules, Tasigna is a protein-tyrosine kinase inhibitor which blocks chemical enzymes in cancer cells in order to inhibit cell growth and division. At recommended doses, Tasigna has been found to set off severe and rapid-onset atherosclerosis. Atherosclerosis is a dangerous thickening of the body's arterial walls, caused by an increase in white blood cells and fibrofatty plaque buildup.

Atherosclerosis can lead to the life-threatening and irreversible health condition known as peripheral arterial disease (PAD). Peripheral arterial disease has dangerous outcomes, including lack of blood flow to the limbs causing tissue death and infection; the amputation of one or more limbs; severe cardiovascular problems; and death. Intending to treat one life-threatening condition, countless patients have taken Tasigna only to suffer from severe Tasigna side effects.

Tasigna Complications Research

The first major peer-reviewed study which specifically examined Tasigna atherosclerosis was published in the American Journal of Hematology. Using post-market clinical data, the study concluded that 25% of Tasigna patients experienced a "vascular event" and 16% suffered from peripheral arterial disease. The findings of this first Tasigna side effects study have been echoed in many studies since, originating from the U.S., Canada and Europe. In 2013 alone, nine different Tasigna atherosclerosis studies were published, including a review of literature from the FDA which found a strong connection between Tasigna and atherosclerosis. On the basis of its findings linking Tasigna and peripheral artery disease, the FDA recommended the addition of a Tasigna side effects warning regarding atherosclerosis and peripheral artery disease be added to the drug label.

Tasigna Atherosclerosis Warning

Tasigna Warnings

The drug label was amended to include a mention of peripheral artery disease, yet a major FDA Tasigna warning was never issued. Novartis officials have known of the risk of Tasigna amputations, peripheral artery disease and death yet never warned physicians or consumers in the United States. Novartis did, however, issue a Tasigna warning in Canada in cooperation with the country's national health organization, urging physicians to monitor patients closely for signs of atherosclerosis. In the United States, Novartis kept the Tasigna risk quiet and continued to aggressively - and sometimes illegally - promote the drug to leukemia patients. Countless American patients have been permanently harmed or lost their lives as a result of Novartis' actions.

Let Our Tasigna Lawyers Help You

Our attorneys specialize in holding large corporations accountable when they've placed profits ahead of safety. Through settlements and winning verdicts, our attorneys have obtained millions for our clients. Let us help you today.

Tasigna Atherosclerosis Lawsuits

Filing a lawsuit will allow you to hold the pharmaceutical company accountable for damage it has caused you or a loved one, while also providing real compensation for your medical expenses, suffering and loss. Contact us today for a free consultation.

Onder Law Has Been Covered By:

Onder Law on ABC News Onder Law on the New York Times Onder Law on USA Today Onder Law on Chicago Tribune Onder Law on LA Times Onder Law on Nightline